GLP-1 drugs have been approved for the treatment of diabetes and obesity, meaning that the FDA has determined that for people with these disorders, the benefits of taking the drug outweigh the potential risks
Regarding renal health, the medication itself is not nephrotoxic, but the side effects (vomiting, diarrhea) can lead to dehydration, which may injure the kidneys
Adjusted BMI thresholds for different ethnic backgrounds One of the most important but least discussed aspects of BMI and GLP-1 eligibility involves ethnic and racial differences in how BMI correlates with metabolic risk
[Office of disease prevention and health promotion USDoHaHS
Miura M, Igarashi M, Isotani R, Nakagawa-Nagahama Y, Kuranami S, Naruse K, et al
Thyroid that's mild and improving doesn't require medical intervention